<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4303</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>4305</td>
<td><strong>SPECIAL FEATURES</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Editorial</strong></td>
<td>Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko</td>
</tr>
<tr>
<td></td>
<td><strong>Food and Oral Antineoplastics: More Than Meets the Eye</strong></td>
<td>Windy Berkofsky-Fessler, Monica Buzza, Marianne K-H. Kim, Steven Fruchtmann, Vesna Najfeld, Dong-Joon Min, Fabricio F. Costa, Jared M. Bischof, Marcelo B. Soares, Melanie Jane McConnell, Weiija Zhang, Ross Levine, D. Gary Gilliland, Raffaele Calogero, and Jonathan D. Licht</td>
</tr>
<tr>
<td></td>
<td><strong>Personalized Tamoxifen: A Step Closer but Miles To Go</strong></td>
<td>Aditya Bardia and Vered Stearns</td>
</tr>
<tr>
<td></td>
<td><strong>Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia</strong></td>
<td>Dennis J. Goussetis and Leonidas C. Platanias</td>
</tr>
<tr>
<td></td>
<td><strong>New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts</strong></td>
<td>Donghui Li and James L. Abbruzzese</td>
</tr>
<tr>
<td>4339</td>
<td><strong>Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F</strong></td>
<td>Windy Berkofsky-Fessler, Monica Buzza, Marianne K-H. Kim, Steven Fruchtmann, Vesna Najfeld, Dong-Joon Min, Fabricio F. Costa, Jared M. Bischof, Marcelo B. Soares, Melanie Jane McConnell, Weiija Zhang, Ross Levine, D. Gary Gilliland, Raffaele Calogero, and Jonathan D. Licht</td>
</tr>
<tr>
<td>4353</td>
<td><strong>Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification</strong></td>
<td>Sara De Brouwer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmin Hoebeek, Tom Van Maerken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huiib Caron, Angelika Eggert, Jan Cools, Rogier Versteeg, and Frank Speleman</td>
</tr>
<tr>
<td>4363</td>
<td><strong>Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity</strong></td>
<td>Shih Shengiang, Wen-Tsen Fang, Ya-Hsue Hou, Shiu-Feng Huang, B. Liniju Yen, Jun-Liang Chang, Shih-Miao Li, Hui-Ping Liu, Ying-Lan Liu, Chih-Ting Huang, Yu-Wei Li, Te-Hsuan Iang, Shih-Hsuan Chan, Su Jing Yang, Chao A. Hsiung, Cheng-Wen Wu, Lu-Hai Wang, and I-Shou Chang</td>
</tr>
<tr>
<td>4331</td>
<td><strong>U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab</strong></td>
<td>Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilano, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur</td>
</tr>
</tbody>
</table>
The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group

Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma
Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jeng, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

CANCER THERAPY: PRECLINICAL

Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation
Javier Redondo-Muñoz, Elizabeth Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, Maríta José Terol, José A. García-Marco, and Angeles García-Pardo
See commentary p. 4311

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines
Haishan Xu and Geoffrey W. Krystal

CANCER THERAPY: CLINICAL

Preclinical and Clinical Evidence that Deoxy-2-[¹⁸F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
Soonmo Peter Kang and Mark J. Ratain
See commentary p. 4305

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients
Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture

IMAGING, DIAGNOSIS, PROGNOSIS

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer
Marco Alifano, Frédérique Souazé, Sandra Dupoux, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaid, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boaron, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch

ABOUT THE COVER
This is an original study providing, from preclinical models to patients, a reliable proof of $^{18}$FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an $^{18}$FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor $^{18}$FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.
Clinical Cancer Research

16 (17)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/17

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/16/17.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.